Anaptysbio (ANAB) EBIT (2016 - 2026)
Anaptysbio (ANAB) reported EBIT of -$34.6 million for Q1 2026, down 25.77% on a YoY basis from -$46.7 million in Q1 2025, and down 151.77% quarter-over-quarter from $66.9 million in Q4 2025.
Anaptysbio (ANAB) EBIT (2016 - 2026) Analysis & Trends
Anaptysbio has reported EBIT for 11 years, with the latest figure at -$34.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 25.77% year-over-year to -$34.6 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (up 357.63% YoY), and the FY2025 full-year result was $47.9 million, up 257.05% from the prior year.
- EBIT for Q1 2026 stood at -$34.6 million, down from $66.9 million in the prior quarter.
- The five-year high for EBIT was $87.9 million in Q4 2023, with the low at -$44.4 million in Q1 2023.
- Historically, EBIT has averaged -$9.8 million across 5 years, with a median of -$27.8 million in 2022.
- Annual changes were most pronounced in 2022 — EBIT tumbled 5115.57% — and 2023, when it soared 438.49%.
- Anaptysbio's EBIT stood at -$26.0 million in 2022, then soared by 438.49% to $87.9 million in 2023, then retreated by 14.94% to $74.8 million in 2024, then declined by 10.54% to $66.9 million in 2025, then plunged by 151.77% to -$34.6 million in 2026.
- The last three EBIT figures came in at -$34.6 million (Q1 2026), $66.9 million (Q4 2025), and $34.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | -34.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.64 Mn |
| Dec 31, 2025 | 66.90 Mn |
| Sep 30, 2025 | 34.70 Mn |
| Jun 30, 2025 | -26.17 Mn |
| Mar 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | 74.78 Mn |
| Sep 30, 2024 | -22.76 Mn |
| Jun 30, 2024 | -40.32 Mn |
| Mar 31, 2024 | -42.20 Mn |
| Dec 31, 2023 | 87.92 Mn |
| Sep 30, 2023 | -37.73 Mn |
| Jun 30, 2023 | -40.14 Mn |
| Mar 31, 2023 | -44.40 Mn |
| Dec 31, 2022 | -25.97 Mn |
| Sep 30, 2022 | -29.63 Mn |
| Jun 30, 2022 | -27.80 Mn |
| Mar 31, 2022 | -31.75 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -6.76 Mn |
| Jun 30, 2021 | -533,000.00 |